
David M. Jablons,
M.D.
Professor and Chief, Section of General Thoracic Surgery
Program Leader, Thoracic Oncology Program

The newly created Chair in Thoracic Oncology is in honor of thoracic oncologist Thierry Jahan, M.D.

A benefit for Lung Cancer Research and to celebrate the Addario Lung Cancer Medical Institute.
A gift to the Thoracic Oncology Progam helps us discover new treatments and cures for lung cancer, esophageal cancer and mesothelioma.
![]() Biao He, Ph.D. Assistant Adjunct Professor of Surgery
Biao He is a molecular geneticist in the Thoracic Oncology Laboratory. Dr. He was recruited for his knowledge of Wnt signaling and RNA interference (RNAi). His current research includes exploration of the molecular mechanisms of non-small cell lung cancer and malignant mesothelioma and development of novel targeted small molecule and monoclonal antibody therapies.
|
![]() Minh To, Ph.D. Assistant Adjunct Professor of Surgery Minh To is a molecular geneticist/biologist and a member of the UCSF Thoracic Oncology Program and Lab. His current research utilizes mouse models to study the mechanism of lung cancer susceptibility and biology, and to identify of novel targets for therapeutic intervention. Dr. To is also heavily involved in a collaborative study with Drs. Allan Balmain and David Jablons that uses a "systems genetics" approach for large scale molecular analysis of human lung cancers in relation to clinical outcomes. |
![]() Zhidong Xu, Ph.D. Assistant Adjunct Professor of Surgery
Zhidong Xu, Ph.D. is a molecular biologist and senior scientist in the Thoracic Oncology Laboratory. In 1998, Dr. Xu was recruited by David M. Jablons, MD to the Thoracic Oncology Laboratory. In 2001, he joined the faculty at the UCSF School of Medicine as an Assistant Professor in the Department of Surgery. |
![]() Liang You, M.D., Ph.D Assistant Adjunct Professor of Surgery Liang You came to the Thoracic Oncology Laboratory after several years at the National Cancer Institute. Dr. You has helped identify several novel biomarkers and therapeutic targets in lung cancer and mesothelioma. He is currently investigating recombinant human WIF-1 protein as a cancer therapy and seeking out new therapeutic targets and novel interventions. |